Author attribution not recorded
Asking uncomfortable questions about a very familiar medicine.
How we got here
Paracetamol (acetaminophen) earned its place on pharmacy shelves long before modern pediatric safety standards focused on long-term neurodevelopmental outcomes. The assumption of safety in children has rested largely on short-term hepatic safety at therapeutic doses—important, but not the same as “safe for the developing brain.” A 2022 systematic review in the European Journal of Pediatrics tracked the citations behind claims of pediatric safety and found no trials that actually evaluated long-term neurodevelopment; safety claims were effectively extrapolated from brief follow-up studies aimed at other outcomes.¹
What newer human studies suggest
Large, modern observational datasets paint a complex picture:
A nationwide Swedish cohort with sibling-control analyses (2.48 million births, 1995–2019) reported that modest risk elevations seen in conventional models disappeared when comparing exposed vs unexposed siblings, arguing that earlier associations may reflect confounding rather than a causal effect.²
Biomarker studies that avoid recall bias are less reassuring: umbilical-cord acetaminophen metabolites tracked in a US birth cohort showed dose-response associations with later ADHD and ASD diagnoses.³
A 2025 Nature Mental Health study linking maternal plasma biomarkers, placental gene expression, and child ADHD found higher odds of ADHD when acetaminophen was detected in second-trimester plasma, and outlined plausible placental pathways.⁴
A 2025 Environmental Health review using the Navigation Guide methodology concluded the balance of evidence is consistent with an association between prenatal acetaminophen exposure and neurodevelopmental disorders, while emphasizing heterogeneity and the limits of observational data.⁵
Taken together, the totality of evidence remains mixed: high-quality sibling designs temper simple causal interpretations, but multiple biomarker and mechanistic studies continue to raise concern.²–⁵
A precautionary drumbeat is growing
In 2021, a multi-disciplinary consensus statement in Nature Reviews Endocrinology called for precautionary action around acetaminophen use in pregnancy, highlighting converging epidemiologic and experimental signals.⁶
Regulators, meanwhile, have tightened risk-mitigation around harms that are unequivocal. Australia’s TGA has mandated smaller pack sizes and blister packaging from 1 February 2025 to reduce intentional overdose and related liver injuries—moves about access and safety engineering, not neurodevelopment.⁷ The US FDA added a boxed-warning-level communication in 2013 about rare but serious skin reactions (SJS/TEN/AGEP).⁸
Would paracetamol be approved for kids today?
Probably not on the basis of historical evidence alone. Modern frameworks expect paediatric formulations to be supported either by paediatric trials, paediatric investigation plans, or, for OTCs, robust monograph conditions—plus growing attention to long-term neurodevelopment when exposure occurs in early life. In the US, acetaminophen’s OTC status is governed by the Internal Analgesic monograph (21 CFR Part 343; Monograph M013) rather than a contemporary paediatric NDA; that pathway does not require new long-term neurodevelopmental studies for legacy actives.⁹,¹⁰ Australia relies on an OTC medicine monograph (most recently updated October 2024) that sets labeling and quality standards but likewise does not establish neurodevelopmental safety.¹¹
Notably, in October 2024 the FDA finalised guidance urging sponsors to consider long-term neurodevelopmental safety studies when products are intended for neonatal use—reflecting an evolving bar for what “safe” should mean in the youngest brains.¹²
Should we keep recommending it in our patients?
Two truths must coexist:
For short-term relief of pain or fever, paracetamol remains an effective antipyretic/analgesic with a wide therapeutic index when dosed correctly, and it is often the only practical option in specific clinical contexts. The American Academy of Paediatrics has long cautioned that the goal in a febrile child is comfort—fever itself is not an illness—and that antipyretics should be used judiciously.¹³
The neurodevelopmental question is not settled. Reasonable, precautionary steps include: avoiding routine/prophylactic use; using the lowest effective dose for the shortest necessary duration; double-checking that families are not “stacking” hidden acetaminophen from combination products; and considering clinical alternatives (e.g., ibuprofen in appropriate children >6 months without contraindications) when equally suitable. These are practical risk-management choices while the evidence base continues to clarify.¹,²–⁶,¹¹,¹²
Bottom line
Paracetamol’s paediatric “safety” was never established on neurodevelopmental endpoints, and contemporary evidence is mixed but cannot exclude harm—especially in biomarker-based and mechanistic studies.¹–⁵,⁶ Caution, transparency with parents, and dose/duration discipline are warranted while stronger causal evidence accumulates. As a clinician-parent, I err on the side of minimising exposure; others may reasonably choose differently after an informed discussion.¹,²–⁶
References
Cendejas-Hernández J, Sarafian JT, Lawton VG, et al. Paracetamol (acetaminophen) use in infants and children was never shown to be safe for neurodevelopment: a systematic review with citation tracking. Eur J Pediatr. 2022;181(5):1835-1857. doi:10.1007/s00431-022-04407-w. SpringerLink
Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen use during pregnancy and children’s risk of autism, ADHD, and intellectual disability. JAMA. 2024;331(13):1205-1214. doi:10.1001/jama.2024.3172. JAMA Network
Ji Y, Azuine RE, Zhang Y, et al. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of ADHD and ASD in childhood. JAMA Psychiatry. 2020;77(2):180-189. doi:10.1001/jamapsychiatry.2019.3259. JAMA Network
Baker BH, Bammler TK, Barrett ES, et al. Associations of maternal blood biomarkers of prenatal APAP exposure with placental gene expression and child ADHD. Nat Ment Health. 2025;3:318-331. doi:10.1038/s44220-025-00387-6. Nature
Prada D, Ritz B, Bauer AZ, et al. Evaluation of the evidence on acetaminophen use and neurodevelopmental disorders using the Navigation Guide methodology. Environ Health. 2025;24:56. doi:10.1186/s12940-025-01208-0. BioMed Central
Bauer AZ, Swan SH, Kriebel D, et al. Paracetamol use during pregnancy — a call for precautionary action. Nat Rev Endocrinol. 2021;17(12):757-766. doi:10.1038/s41574-021-00553-7. Nature
Therapeutic Goods Administration (TGA). TGA makes final decision to reduce paracetamol pack sizes (Media release). 3 May 2023. Accessed 14 Aug 2025. https://www.tga.gov.au/… Therapeutic Goods Administration (TGA)
US Food and Drug Administration (FDA). Drug Safety Communication: FDA warns of rare but serious skin reactions with acetaminophen. 1 Aug 2013. Accessed 14 Aug 2025. https://www.fda.gov/… [source link unavailable; citation retained] U.S. Food and Drug Administration [source link unavailable; citation retained]
Electronic Code of Federal Regulations. 21 CFR Part 343 — Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for OTC Human Use. Accessed 14 Aug 2025. https://www.ecfr.gov/… eCFR
FDA. OTC Monograph M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for OTC Human Use (Labeling excerpt; posted Oct 14, 2022). Accessed 14 Aug 2025. https://dps-admin.fda.gov/… FDA
TGA. Over-the-counter (OTC) medicine monograph: Paracetamol for oral use (updated 16 Oct 2024). Accessed 14 Aug 2025. https://www.tga.gov.au/… Therapeutic Goods Administration (TGA)
FDA. Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry (final). Oct 2024. Accessed 14 Aug 2025. https://www.fda.gov/media/165239/download. U.S. Food and Drug Administration
Sullivan JE, Farrar HC; American Academy of Pediatrics, Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. Pediatrics. 2011;127(3):580-587. doi:10.1542/peds.2010-3852. AAP Publications